Cargando…

Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling

INTRODUCTION: The androgen receptor (AR) is the most highly expressed steroid receptor in breast cancer with 75–95% of estrogen receptor (ER)-positive and 40–70% of ER-negative breast cancers expressing AR. Though historically breast cancers were treated with steroidal androgens, their use fell from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narayanan, Ramesh, Ahn, Sunjoo, Cheney, Misty D., Yepuru, Muralimohan, Miller, Duane D., Steiner, Mitchell S., Dalton, James T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114483/ https://www.ncbi.nlm.nih.gov/pubmed/25072326 http://dx.doi.org/10.1371/journal.pone.0103202

Ejemplares similares

An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancers
por: Rajarajan, Savitha, et al.
Publicado: (2023)

Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation
por: Narayanan, Ramesh, et al.
Publicado: (2013)

Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7
por: Yin, Yinfei, et al.
Publicado: (2010)

Selective androgen receptor modulators in preclinical and clinical development
por: Narayanan, Ramesh, et al.
Publicado: (2008)

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
por: Brumec, Maša, et al.
Publicado: (2021)

Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus
por: Simitsidellis, Ioannis, et al.
Publicado: (2019)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

MicroRNAs Are Mediators of Androgen Action in Prostate and Muscle
por: Narayanan, Ramesh, et al.
Publicado: (2010)

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2017)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
por: Mina, Alain, et al.
Publicado: (2017)

Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models
por: Tesei, Anna, et al.
Publicado: (2013)

SARM1 detection in myelinating glia: sarm1/Sarm1 is dispensable for PNS and CNS myelination in zebrafish and mice
por: Fazal, Shaline V., et al.
Publicado: (2023)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology
por: Chen, Chiung-Ya, et al.
Publicado: (2011)

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
por: Thakkar, A., et al.
Publicado: (2016)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Speers, Corey, et al.
Publicado: (2017)

Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone)
por: Padappayil, Rana Prathap, et al.
Publicado: (2022)

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer
por: Narayanan, Ramesh, et al.
Publicado: (2017)

Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
por: Narayanan, Ramesh, et al.
Publicado: (2016)

Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature
por: Mohamed, Wael T, et al.
Publicado: (2023)

Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
por: Wang, Changjun, et al.
Publicado: (2016)

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features
por: Astvatsaturyan, Kristine, et al.
Publicado: (2018)

Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer
por: Lee, Reeree, et al.
Publicado: (2022)

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria
por: Haruna, Muibat, et al.
Publicado: (2022)

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?
por: Dubrava, Alex L, et al.
Publicado: (2023)

Necroptosis is SARMful to your health
por: Pierchala, Brian A.
Publicado: (2020)

Identification and Synthesis of Selected In Vitro Generated Metabolites of the Novel Selective Androgen Receptor Modulator (SARM) 2f
por: Möller, Tristan, et al.
Publicado: (2023)

Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
por: Pistelli, Mirco, et al.
Publicado: (2014)

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor
por: Doberstein, Kai, et al.
Publicado: (2014)

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
por: Bhattarai, Shristi, et al.
Publicado: (2019)

Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer
por: Hu, Xiao-Qing, et al.
Publicado: (2017)

Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients
por: Govindan, Sindhu, et al.
Publicado: (2020)

Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2019)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling
por: Zhang, Jianchao, et al.
Publicado: (2016)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer
por: Zheng, Qianqian, et al.
Publicado: (2020)

Molecular Classification of Triple-Negative Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_61r3v1p5vj3mu0aklr8d81q30m